Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor regressions in patients with advanced MCC. However, there is a paucity of data regarding ef...

Descripción completa

Detalles Bibliográficos
Autores principales: LoPiccolo, Jaclyn, Schollenberger, Megan D., Dakhil, Sumia, Rosner, Samuel, Ali, Osama, Sharfman, William H., Silk, Ann W., Bhatia, Shailender, Lipson, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615256/
https://www.ncbi.nlm.nih.gov/pubmed/31287031
http://dx.doi.org/10.1186/s40425-019-0661-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615256/
https://www.ncbi.nlm.nih.gov/pubmed/31287031
http://dx.doi.org/10.1186/s40425-019-0661-6

Ejemplares similares